Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Novo Nordisk looks to Flagship Pioneering start-up for next weight-loss play

by Rowan Walrath
May 16, 2024 | A version of this story appeared in Volume 102, Issue 15

 

Following the massive success of Wegovy, Novo Nordisk is tapping Flagship Pioneering–backed molecular-mimicry start-up Metaphore Biotechnologies for its next suite of weight-loss drugs. Novo will pay up to $600 million for Metaphore to discover and finish preclinical development of up to two multitarget weight-loss medicines, after which point the Danish firm will take over clinical development and commercialization. The firms did not disclose additional details as to the drug targets. Venture firm Flagship launched Metaphore 1 year ago to mimic pharmacophores to go after biological targets that have so far been difficult to drug.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.